Reperfusion treatment in acute myocardial infarction represents the main indication for
thrombolytic therapy. The most common thrombolytic agents have been streptokinase (first …

Coronary artery disease is the single leading cause of death in the United States. Occlusion
of the coronary artery was identified to be the cause of myocardial infarction almost a century …

Cardiovascular diseases, comprising acute myocardial infarction (AMI), stroke and venous
thromboembolism have, as their immediate underlying cause, thrombosis of critically …

The ability of thrombolytic therapy to lower mortality in patients with acute myocardial
infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della …

Background: Certain shortcomings of the available thrombolytic agents have prompted the
search for a more fibrin specific fibrinolytic agent with a longer half-life. Such properties …

In the past 10 years, thrombolytics have become standard therapy for acute myocardial
infarction. Although the ability of streptokinase to lyse clot was first recognised in the 1930s …

OBJECTIVE: To review the literature on the use of thrombolytic agents in the
pharmacotherapeutic management of acute myocardial infarction (AMI). DATA SOURCE …

Thrombotic complications of cardiovascular disease are a main cause of death and disability
and, consequently, thrombolysis could favorably influence the outcome of such life …

Background: The comparative clinical effectiveness of new (reteplase, tenecteplase) vs.
older (alteplase, streptokinase) thrombolytic agents in the treatment of acute myocardial …

Thrombolytic therapy of acute myocardial infarction is based on the premise that coronary
artery thrombosis is its proximate cause. Rupture of atheromatous plaque leads to occlusive …